Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
월요일, 8월 31

Arcutis Biotherapeutics Inc

ARQTNASDAQ
Trade with Public
Trade with Public
$23.83
0.0490.21%
마지막 업데이트: Aug 31, 3:31 PM
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Arcutis Biotherapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Arcutis Biotherapeutics (ARQT).

Price Target Range — 13 Quarters

Analyst Consensus — 9 Analysts

7Buy
2Hold
Consensus RatingBuy# Analysts9Avg. Consensus PT$29Upside to Avg. PT+22.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 6, 2026Morgan StanleyVikram PurohitPT RaiseOverweight$34→$38
Aug 6, 2026GuggenheimSeamus FernandezPT RaiseBuy$35→$38
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38

Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and raises the price target from $34 to $38.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38

Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $38.
Benzinga Newsdesk

PRO
Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $36 to $40.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $36 Price Target

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $36 price target.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Arcutis Biotherapeutics, Lowers Price Target to $35

Mizuho analyst Uy Ear maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Outperform and lowers the price target from $37 to $35.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $35

Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $34 to $35.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved